Please login to the form below

Not currently logged in
Email:
Password:

ivabradine

This page shows the latest ivabradine news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    While Entresto has captured the headlines of late, there was another key development in HF therapy this year after Amgen secured approval in the US for Corlaner (ivabradine), a drug that ... Ivabradine is thought to be the first drug to work by

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... Over 40 European countries, Australia, New Zealand . ‡ North America. ‡‡ Amgen receives

  • Pharma deals during July 2013 Pharma deals during July 2013

    Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics